GC203 TIL

N/A

Report date: 2026/04/17 10:35:59

Base Information

Drug NameGC203 TIL
Drug Alias NameTIL engineered with membrane-binding cytokine (GC203 TIL)Membrane Bound Cytokine Modified TILTumour infiltrating lymphocyte (TIL) engineered with membrane-binding cytokine therapyGC203 TILGC-203
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionLymphocyte replacementsImmunologic cytotoxicityCytokine replacements
TargetsCytokines
Therapy Area/IndicationsSolid tumoursDrug-Related Side Effects and Adverse ReactionsGenital Neoplasms, Female +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Junsai Biological Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Junsai Biological Co LtdShanghai Junsai Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursDrug-Related Side Effects and Adverse ReactionsGenital Neoplasms, Female +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A